Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Inks DNA Testing Contract with New Zealand

NEW YORK, April 13 (GenomeWeb News) - Orchid BioSciences Europe will provide DNA testing services to the New Zealand immigration authorities, parent company Orchid BioSciences said today.


Under the three-year contract, which is potentially renewable for two years, Orchid will test DNA samples from applicants seeking residency in New Zealand to determine their biological relationships to family members.


Under New Zealand law, certain relatives of citizens and permanent residents are allowed to immigrate. DNA testing will be applied to applicants from countries with record systems that do not satisfy the requirements of the New Zealand Immigration Service.


Orchid BioSciences Europe, based in Abingdon, UK, already provides immigration DNA testing for the UK and Norway. The company resulted from Orchid's acquisition of Cellmark Diagnostics in 2001.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.